No Data
UBS Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $38
Jasper Therapeutics (JSPR) Gets a Buy From UBS
UBS Initiates Coverage On Jasper Therapeutics With Buy Rating, Announces Price Target of $38
Jasper Therapeutics To Present On Briquilimab At American Academy Of Allergy, Asthma, And Immunology Annual Meeting
Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference
